Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms26010061 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rosanna Squitti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. Hauptthemen laut MEDLINE: Neurofilament Proteins, Biomarkers, Mental Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health, Italy (Ricerca Corrente).
Abstract (Originalsprache)
Severe mental disorders (SMDs), such as schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD), are heterogeneous psychiatric diseases that impose a significant societal burden due to their chronic disabling nature. There are no objective and reliable diagnostic tests for SMDs; thus, there is an urgent need for specific biomarkers to improve diagnosis, treatment, and resource allocation. Neurofilaments, found in cerebrospinal fluid and blood, offer reliable diagnostic and prognostic potential. This review discusses the link between neurofilament light chain (NfL) involvement in psychiatric and neurodegenerative diseases and gives insights into the diagnostic and prognostic value of NfL in SMDs. This systematic review searched PubMed, Scopus, and Web of Science databases to answer the research question “Are NfL levels higher in individuals with SMDs compared to healthy controls?” using terms related to neurofilament, SMDs, SZ, BD, and depression. Of 8577 initial papers, 115 were relevant. After exclusions and manual additions, 17 articles were included. Studies indicate elevated NfL levels in SMDs compared to healthy controls, suggesting its potential as a biomarker for SMDs and for distinguishing neurodegenerative diseases from psychiatric disorders. However, further longitudinal research is needed to confirm its reliability for differential diagnosis, disease prediction, and treatment assessment in psychiatry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.
- Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
- Department of Psychology, Uninettuno University, 00186 Rome, Italy.
- Unit of Epidemiological and Evaluation Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
ORCID-Profile: Rosanna Squitti, Viviana Brembati, Daniela Crescenti, Roberta Ghidoni
Förderung
- Italian Ministry of Health
- Italian Ministry of Health, Italy (Ricerca Corrente)
Zitieren
APA
Squitti, R., Fiorenza, A., Martinelli, A., Brembati, V., Crescenti, D., Rongioletti, M., & Ghidoni, R. (2024). Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010061
Vancouver
Squitti R, Fiorenza A, Martinelli A, Brembati V, Crescenti D, Rongioletti M, et al. Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010061
BibTeX
@article{Squitti2024,
author = {Squitti, Rosanna and Fiorenza, Antonio and Martinelli, Alessandra and Brembati, Viviana and Crescenti, Daniela and Rongioletti, Mauro and Ghidoni, Roberta},
title = {Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms26010061}
}
EUVIMED